

# R&D PORTFOLIO June 2023 - 12 treatments delivered

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
Sleeping sickness							Acoziborole +	Fexinidazole for <i>T.b. rhodesiense</i> +	Fexinidazole for <i>T.b. gambiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*
Leishmaniasis	Screening		S07 series +	DNDI-6174 +	DNDI-6148 +	LXE408 Novartis for VL +	Miltefosine + thermo-therapy for CL	Miltefosine + paromomycin for VL (Africa)	SSG + PM (East Africa)* New VL treatments (South Asia)* New treatments for VL/HIV* New VL treatments (Latin America)*
					DNDI-0690 +		LAmB +/- miltefosine for PKDL (Asia)		
					DNDI-6899 (GSK899 DDD853651) +		Miltefosine + paromomycin or LAmB for PKDL (Sudan)		
					CpG-D35 (DNDI-2319) +				
					GSK245 (DDD1305143) +				
Chagas disease	Screening	Hit-to-lead	UW series +	Biomarkers	DNDI-6148 +		New benznidazole regimens	Benznidazole paediatric dosage forms*	
Filaria: River blindness				DNDI-6166 (CC6166) +	Oxfendazole +	Emodepside + Flubentylosin +			
Mycetoma							Fosravuconazole		
Dengue				Pre-clinical profiling					
HIV						SR 5FC (cryptococcal meningitis)			Super-booster for children with HIV/TB* 4-in-1 (ABC/3TC/LPV/r)* and other DAAs 2-in-1 LPV/r pellets 5FC, LAmB access (cryptococcal meningitis)
									Ravidasvir* and other DAAs +
Hepatitis C									
COVID-19/ Pandemic preparedness	Nucleo- side Booster		TMEM16 series +						
			Moonshot +						
			AVIDD ASAP +						
Malaria >>								Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*	

>> Implementation transferred to the Medicines for Malaria Venture in 2015

+ New chemical entity (NCE) or NCE-enabling project

\* Treatments delivered by DNDi with partners

▶ Treatments not delivered by DNDi, but DNDi working on access